MXC Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): A$18,852.46
Insider Selling (Last 12 Months): A$0.00

MGC Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at MGC Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

MGC Pharmaceuticals Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 03/18/2020 01:00 AM ET

This chart shows the closing price history over time for MXC up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

MGC Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/6/2022Roby ZomerInsiderBuy819,672A$0.02A$18,852.46
11/24/2021Ross WalkerInsiderExercise600,000A$0.05A$27,000.00
10/7/2021Stephen ParkerInsiderExercise600,000A$0.06A$35,400.00
9/30/2021Evan HayesInsiderBuy295,000A$0.06A$17,700.00
9/9/2021Nativ SegevInsiderIssued2,100,000A$0.06A$126,000.00
3/5/2021Roby ZomerInsiderCancelled2,500,000A$0.07A$165,000.00
8/12/2020Brett MitchellInsiderBuy2,500,000A$0.02A$60,000.00
7/10/2020Brett MitchellInsiderIssued555,554A$0.00A$2,222.22
See Full Table

SEC Filings (Institutional Ownership Changes) for MGC Pharmaceuticals (ASX:MXC)

MGC Pharmaceuticals logo
MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. The company also provides ArtemiC range of products and cannabinoid products, as well as non-pharma products. In addition, it offers consulting services, including clinical research services. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is based in West Perth, Australia.
Read More on MGC Pharmaceuticals

Today's Range

Now: N/A

50 Day Range


52 Week Range

Now: N/A


2,156,322 shs

Average Volume


Market Capitalization


P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of MGC Pharmaceuticals?

MGC Pharmaceuticals' top insider shareholders include:
  1. Evan Hayes (Insider)
  2. Nativ Segev (Insider)
  3. Roby Zomer (Insider)
  4. Ross Walker (Insider)
  5. Stephen Parker (Insider)
Learn More about top insider investors at MGC Pharmaceuticals.
Elon Musk Sees Serious Crisis
When Tesla's Elon Musk says there's a major shortage of a key material used in electric vehicles...and says prices for this material are "CRAZY" can bet there's an incredible investment opportunity in that crisis.
Discover how you can take advantage of lithium